- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04201054
Generation of Biological Samples Positive to Fluconazole for Anti-Doping Control (FLUC)
Background:
Androgens are used for doping purpose because they can increase muscle mass and strength. These drugs are included in the list of prohibited substances of the World Anti-Doping Agency (WADA). The prohibition of its use has given rise to a great variety of strategies, including indirect androgenic doping (increasing endogenous testosterone production) or masking of exogenous testosterone administration.
Fluconazole is an imidazole antifungal that inhibits certain cytochrome P-450 dependent enzymes participating in the synthesis of steroid hormones. Concomitant fraudulent administration of testosterone and fluconazole may cause lower steroid concentrations in urine, leading to false negatives in the doping control. Thus, fluconazole may be used in athletes to mask exogenous steroid administration.
Hypothesis:
The oral administration of 12,5 mg of hydrochlorothiazide in healthy subjects allows generating detectable concentrations of the drug in urine. Positive urine samples will enable to identify analytical strategies for doping control.
Objectives:
Primary objective: To measure the concentrations of fluconazole in urine for anti-doping control samples.
Secondary objectives: To identify fluconazole metabolites in urine. To explore the time window in which the drug or its metabolites can be detected in urine after administration. To assess safety and tolerability of the drug used.
Methods:
Phase I, open, non-randomized clinical trial, with a treatment condition (fluconazole) administered in a single oral dose to 2 subjects.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08003
- IMIM (Hospital del Mar Medical Research Institute)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male volunteers aged between 18 and 45 years.
- Able to understand and accept the trial procedures and able to sign an informed consent.
- History and physical examination that demonstrate not presenting organic or psychiatric disorders.
- ECG, blood and urine tests performed at screening should be within normal limits. Minor or punctual variations of these limits of normality are admitted if, in the opinion of the Principal Investigator, they have no clinical significance, do not pose a risk to the subject and do not interfere with the evaluation of the product in study. These variations and their nonrelevance will be justified in writing specifically.
- Body mass index (weight/size^2) between 19 and 25 kg/m2. Subjects with BMI between 25-27 kg/m2 may be included at the discretion of the Principal Investigator.
Exclusion Criteria:
- Failure to meet the inclusion criteria.
- History of allergy, idiosyncrasy, hypersensitivity or adverse reactions to the active substance or any of the excipients.
- History of serious adverse reactions to other medications.
- Subjects with contraindications to treatment with the study drug (according to Summary of Product Characteristics).
- Background or clinical evidence of psychiatric disorders, alcoholism, regular consumption of psychoactive drugs, drug abuse or addiction to other substances (except for nicotine).
- Smokers of more than 20 cigarettes/day in the 3 months prior to the start of the study.
- Having participated in another clinical trial with medication in the three months prior to the start of the study.
- Having donated blood in the 2 months prior to the start of the study.
- Having suffered an organic disease or major surgery in the 6 months prior to the start of the study.
- Background or clinical evidence of cardiovascular, respiratory, renal, hepatic, endocrine, gastrointestinal, hematological, neurological, dermatological or other acute or chronic diseases that, in the opinion of the Principal Investigator or the collaborators designated by him, may pose a risk to the subjects, may interfere with the objectives of the study or may alter the pharmacokinetics of the drug. Especially in case of seizures or history of epilepsy.
- Having taken medication regularly in the month prior to the study sessions, with the exception of vitamins, herbal remedies or dietary supplements that, in the opinion of the Principal Investigator or the collaborators designated by him, do not pose a risk to the subjects and do not interfere with the objectives of the study. Treatment with single doses of symptomatic medication in the week prior to the study sessions will not be exclusive if it is assumed that medication has been completely eliminated on the day of the experimental session.
- Consumption of more than 40 g of alcohol per day.
- Consumers of more than 5 coffees, teas, cola drinks and/or other stimulant drinks (xanthines) per day in the 3 months prior to the start of the study.
- Being unable to understand the nature of the trial and the procedures requested to follow.
- Positive serology for hepatitis B, C or HIV.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fluconazole
Subjects receive a single-dose treatment.Urine samples will be collected after administration (4 fractions: 0-12, 12-24, 24-48, 48-72 hours post-administration).
|
50 mg of fluconazole administered orally in a single dose.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urine concentration of fluconazole
Time Frame: 0-12 hours post-administration
|
Concentration of fluconazole in fraction-1 urine samples
|
0-12 hours post-administration
|
Urine concentration of fluconazole
Time Frame: 12-24 hours post-administration
|
Concentration of fluconazole in fraction-2 urine samples
|
12-24 hours post-administration
|
Urine concentration of fluconazole
Time Frame: 24-48 hours post-administration
|
Concentration of fluconazole in fraction-3 urine samples
|
24-48 hours post-administration
|
Urine concentration of fluconazole
Time Frame: 48-72 hours post-administration
|
Concentration of fluconazole in fraction-4 urine samples
|
48-72 hours post-administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urine concentration of fluconazole metabolites
Time Frame: 0-12 hours post-administration
|
Concentration of fluconazole metabolites in fraction-1 urine samples
|
0-12 hours post-administration
|
Urine concentration of fluconazole metabolites
Time Frame: 12-24 hours post-administration
|
Concentration of fluconazole metabolites in fraction-2 urine samples
|
12-24 hours post-administration
|
Urine concentration of fluconazole metabolites
Time Frame: 24-48 hours post-administration
|
Concentration of fluconazole metabolites in fraction-3 urine samples
|
24-48 hours post-administration
|
Urine concentration of fluconazole metabolites
Time Frame: 48-72 hours post-administration
|
Concentration of fluconazole metabolites in fraction-4 urine samples
|
48-72 hours post-administration
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Rafael de la Torre Fornell, Dr, IMIM (Hospital del Mar Medical Research Institute)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Fluconazole
Other Study ID Numbers
- IMIMFTCL/FLUC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Hangzhou Sciwind Biosciences Co., Ltd.RecruitingHealthy VolunteersChina
Clinical Trials on Fluconazole
-
AstraZenecaCompletedAsthmaUnited States, Canada, Denmark, France, Italy, Sweden, United Kingdom, Belgium, Taiwan, Brazil, Poland, Russian Federation, Spain, Germany, Argentina, Colombia, Mexico
-
National Hospital for Tropical Diseases, Hanoi,...Centers for Disease Control and Prevention; Hospital for Tropical Diseases,...UnknownHIV/AIDS | Mycosis Fungoides | Cryptococcosis | Cryptococcal Meningitis | Opportunistic Infections, HIV Related | Mycosis; OpportunisticVietnam
-
Radboud University Medical CenterSt. Antonius HospitalCompletedObesity | Candidiasis | Invasive Fungal Infections | FluconazoleNetherlands
-
BayerCompletedPharmacology, ClinicalGermany
-
Daniel BenjaminPediatric Pharmacology Research Units NetworkCompletedCandidiasisUnited States
-
PfizerCompleted
-
Anders Rane, MD, PhD, Senior professorKarolinska University HospitalCompletedBacterial Infections and Mycoses | Ductus Arteriosis, PatentSweden
-
Makerere UniversityGilead Sciences; University of MinnesotaRecruitingCryptococcal MeningitisUganda
-
F2G Biotech GmbHThe Clinical Trials Centre Cologne; Klinik für Hämatologie, Aachen; Medizinische...Withdrawn
-
Benha UniversityRecruiting